Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03369236 · ClinicalTrials.gov registry record · Phase 2
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03369236 is a Phase 2 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 13 participants.
The verdict
NCT03369236, a Phase 2 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary purpose of this proof-of-concept clinical study was to evaluate the efficacy and safety of the study drug, ACH-0144471 (also known as danicopan and ALXN2040), in participants with C3G who also had significant proteinuria attributable to C3G.
Interventions
- DRUG Placebo
- DRUG Danicopan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-06-12 |
| Est. Completion | 2020-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03369236
The ClinicalTrials.gov registry entry for NCT03369236 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03369236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03369236 about?
NCT03369236 is a clinical study titled "A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)". The primary purpose of this proof-of-concept clinical study was to evaluate the efficacy and safety of the study drug, ACH-0144471 (also known as danicopan and ALXN2040), in participants with C3G who also had significant proteinuria attributable to C3G.
What is the current status of trial NCT03369236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2018-06-12. Estimated completion is 2020-12-18.
What interventions are being tested in trial NCT03369236?
The interventions under investigation include: Placebo (DRUG), Danicopan (DRUG).
Who is sponsoring clinical trial NCT03369236?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.